Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iCare4: Midostaurin + Cytarabine in Relapsed/Refractory AML
NCT03207334Phase 2Withdrawn
- Sponsor
- University of Florida
- Start
- Nov 2018
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of midostaurin in acute myeloid leukemia (AML), sponsored by University of Florida. Planned start Nov 2018; status: withdrawn.
02
Drugs
midostaurin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03207334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03207334.